Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Current Quarter	$-1.36	Next Quarter	$-1.64
Current Year	$-4.79	Next Year	$-7.39
QoQ Growth	-20.6%	YoY Growth	-54.3%
3Y EPS CAGR	-220.8%	Target Price	$207.30
Consensus	Buy	Upside	-6.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CDTX	$220.86	0.00%	145.74K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CDTX	$220.86	0%	145.74K
3
4
5
6

CDTX

CDTX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Cidara Therapeutics Inc. Data in Excel

Get Cidara Therapeutics Inc. Data in Excel